Read More

What’s Happening With Eli Lilly Shares On Monday?

Eli Lilly reports detailed results from the SYNERGY-NASH phase 2 study. The trial, involving 190 patients with and without type 2 diabetes, showed tirzepatide met the primary endpoint, achieving MASH resolution without fibrosis worsening. Participants taking 5 mg, 10 mg, and 15 mg doses saw significant improvements compared to placebo, presented at the EASL Congress 2024.

LLY

Read More

Actinium Highlights Mutation Data From The Phase 3 SIERRA Trial Of Iomab-B And Novel Linker Technology To Support Solid Tumor Antibody Radiation Conjugate Development At The 2024 SNMMI Annual Meeting

Iomab-B led bone marrow transplant improved survival in patients with high-risk relapsed or refractory acute myeloid leukemia including those with a TP53 mutationIomab-B safely delivered radiation to the target bone

ATNM

Read More

NRx Pharmaceuticals Publishes Shareholder Update Letter; Update Highlights Potential Implications Of The Company’s Recent Activities At The Annual Meeting Of The American Society Of Clinical Psychopharmacology

The June 2024 meeting of the American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging standard of care for treating

NRXP